BeStock  
Stocks › Biotechnology › SMMT

Summit Therapeutics SMMT

US equityMarket cap rank #1601BiotechnologyTop Gainers Yesterday
$9.95 −$0.62 (-5.87%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $10.08 +1.31%
Open$10.28
Prev close$10.57
Day range$9.89 – $10.61
Volume7.22M
Market cap$7.96B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

SMMT at a glance

Shares of Summit Therapeutics are down 5.87% at $9.95. The company is worth $7.96B, number 1601 out of 3753 on our list.

It is close to the bottom of its 52-week range ($9.89 to $29.23), 66.0% under the high. Holders are behind 38.5% over twelve months, and down 21.8% across the last three months.

On the chart it has slipped under both the 50-day ($15.74) and 200-day ($16.06) moving averages; RSI is 30, and the last 30 sessions moved at roughly 110% annualized volatility.

Revenue for the quarter ended Sep 2026 was $0.00, and a net loss of $208.39M.

13 analysts follow the stock and the average call is "buy". The mean target, $27.57, sits 177.1% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$10.07 / $10.19
Average price today$10.10
Volume7.22MAvg (90d) 6.12M
Turnover$72.90M
Turnover rate4.74%of shares outstanding
Volume ratio0.56vs. recent average pace
Day amplitude6.81%
Market cap$7.96B
Float market cap$1.52B
Shares outstanding152.29M
EPS (TTM)-$1.44
P/B14.09
Book value / share$0.71
Net profit (TTM)-$1.15B
Net assets$564.63M
30-day volatility109.7%annualized
Avg daily range (ATR)14.84%of price, 14 days
Max drawdown (1y)-62.3%-62.3% from 1y peak

Quote as of Nov 21, 2026 9:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

D
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

C
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

F
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

13 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 17.9 · 2026-11-22 08:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation—
Growth—
Profitability12.9
Momentum11.8
Financial health73.6
Analyst view72.0

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$27.57+177.1% vs. current price
Consensus ratingBuy13 analysts covering
Morningstar fair value$18.77Price is below fair value

Wall Street’s average 12-month target is $27.57, 177.1% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $18.77, so shares trade 47.0% below that estimate. On earnings multiple, it sits in the 44th percentile of its own five-year valuation range (cheaper than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-5.9%
1 week
-29.7%
1 month
-36.0%
3 months
-21.8%
6 months
-40.1%
Year to date
-43.1%
1 year
-38.5%
Day range
$9.89$10.61
52-week range
$9.89$29.23

Technical signals

Full technicals →
Trend readStrong downtrend

0 bullish · 7 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-31.4%Bearish
Price vs 50-day average-36.8%Bearish
Price vs 200-day average-38.0%Bearish
50-day vs 200-day50d below 200dBearish
RSI (14)30.3Bearish
MACD (12,26,9)-1.37Bearish
Bollinger band position4%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How SMMT ranks on BeStock

Market value#1597 of 3734
Closeness to 52-week high#3437 of 3724
Dollar volume today#1172 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

SMMT is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on SMMT.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on SMMT

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

SMMT stock: common questions

What is SMMT's latest share price?

$9.95 is the latest print for SMMT, a move of -5.87% against yesterday's close of $10.57. Today's low and high so far: $9.89 and $10.61.

How big is Summit Therapeutics?

Equity value comes to $7.96B at the current price. By that measure it is number 1601 of the 3753 names in our coverage.

Is SMMT near its 52-week high or low?

The year's floor is $9.89 and the ceiling $29.23. Shares are 66.0% away from that ceiling.

Does Summit Therapeutics pay a dividend?

Our data shows no dividend paid by Summit Therapeutics over the trailing twelve months.

Is SMMT rated a buy by Wall Street?

Of 13 analysts, 62% say buy, 31% hold and 8% sell. Price targets average $27.57, with the most cautious at $8.30 and the most optimistic at $43.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on SMMT.

Sign in to join the discussion.

Scroll to Top